drugset / Trial / NCT01317004
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs. DMT standard of care, using the global satisfaction subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM-9).
Timeline
- Start
- 2011-05
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fingolimod | Small molecule | 0.5 mg | Oral |
| Comparator | Glatiramer Acetate | Small molecule | — | — |
| Comparator | Interferon beta-1a | Protein / enzyme biologic | — | — |
| Comparator | Interferon beta-1b | Protein / enzyme biologic | — | — |